Abstract
biological pathways to characterize cancer and other diseases. By considering the distribution 38 of gene-and subnetwork-based biomarkers, we show that pathway data improves improvements in biomarker performance, then identifying informative groups of genes is 83 clearly a more efficient approach to generating clinically relevant prognostic tools.
84
To resolve this issue, we examined whether using subnetworks as the building blocks of 85 prognostic biomarkers confers any advantage over orthodox gene-based approaches. The 86 SIMMS model was generalized to score gene biomarkers as well as subnetwork biomarkers 87 and then used to evaluate and compare the performance of 22,000,000 gene biomarkers and 
Results and discussion

95
Using SIMMS to measure the performance of gene and subnetwork biomarkers 96 The prognostic performance of subnetwork biomarkers was evaluated on a 4,960 breast 97 cancer patient meta-dataset using the SIMMS model as fully detailed in Methods [28] . Cox model is fit to the patient risk scores of the subnetworks comprising the biomarker.
To study the characteristics of the population of gene biomarkers and subnetwork biomarkers, 114 we randomly sampled 22,000,000 gene biomarkers and 6,250,000 subnetwork biomarkers by 115 utilizing jackknifing, a resampling method in which samples are drawn from a population 116 without replacement [34] . For this purpose, we only used genes for which mRNA abundance 117 scores were available in all eighteen datasets comprising our breast cancer meta-dataset 118 (Table 1) . To ensure that our set of gene biomarkers contained the same underlying mRNA 119 abundance data as our set of subnetwork biomarkers, all gene biomarkers were drawn from a 120 pool of the 1,500 genes which were included in at least one of the 500 subnetworks from 121 which the subnetwork biomarkers were created. Since gene biomarkers were drawn from a 122 set of 1,500 features while subnetwork biomarkers were drawn from a set of 500 features, the 123 population of all possible gene biomarkers is substantially larger than that of all possible subnetwork biomarkers. This necessitated a larger test set of gene biomarkers to fully capture 125 the null distribution of gene biomarker performance. The prognostic capability of each gene 126 and subnetwork biomarker was estimated using SIMMS on twenty different partitions of the 127 breast cancer meta-dataset, each of which was composed of varying training and testing 128 cohort sizes (Tables 2-3 ). For full details on how the meta-dataset was partitioned, see
129
Methods.
130
Considering only a single meta-dataset partition of equally-sized training and testing cohorts 131 (the 'default' partition in Table 2 ), we found that the performance of gene and subnetwork plateauing at around 100 subnetworks.
139
Comparison of gene and subnetwork biomarkers across gene counts
140
To better contrast the performance of gene and subnetwork biomarkers, we first normalized 141 the sizes of our subnetwork biomarkers to make them more directly comparable to our gene 142 biomarkers. Since a subnetwork biomarker is essentially a set of gene lists, the most 143 straightforward way to perform this normalization is to simply sum the sizes of all these gene 144 lists to get the total number of genes in the biomarker. However, there is gene content overlap in our set of 500 subnetworks so a single subnetwork biomarker may include multiple 146 subnetworks that contain the same gene. Therefore, we additionally considered the number of 147 unique genes in each biomarker. At each gene count, we compared the 95th to 99th 148 percentiles of subnetwork biomarker performance against the 95th to 99th percentiles of gene 149 biomarker performance (Figure 2 ).
150
The difference in performance between the two gene count normalization techniques is 151 negligible as both gene and subnetwork biomarkers exhibit similar peak performance.
152
Although gene biomarkers require fewer genes to reach optimal prognostic efficiency, they 153 also show a higher propensity for over-fitting at higher gene counts.
154
Randomly sampling training:testing meta-dataset partitions reveals effect of training 155 cohort size on biomarker performance and stability
156
To test the robustness of our finding that biomarker size affects performance, we re-evaluated to biomarker size remain the same even though the performance of both gene and 161 subnetwork biomarkers decreases slightly overall in this setting. However, subnetwork 162 biomarkers do reach higher peak performance than gene biomarkers, suggesting that they 163 are less sensitive to a suboptimal training environment. To verify these observations, we went 164 on to create eighteen more meta-dataset partitions using random sampling for a total of ten 165 partitions with larger training cohorts and ten partitions with smaller training cohorts.
As first evidenced by our initial finding, both gene and subnetwork biomarkers perform 167 routinely better when trained on the larger patient cohorts (Figure 3) 
Conclusions
218
In this study, we applied jackknifing to a 4,960 breast cancer patient meta-dataset and The breadth of our analysis also allows us to make several other important observations 229 about prognostic biomarker performance and robustness. Small training cohort sizes have a greater effect on overall biomarker performance than on the consistency of said performance.
231
Furthermore, the performance of large biomarkers is substantially more unstable than that of 232 small biomarkers. Therefore, to optimize biomarker development, it is critical to maximize 233 training cohort size and to minimize biomarker size.
234
Nevertheless, we recognize there are several caveats to be made regarding our findings that Finally, deeply sampling the total biomarker space allows for a comprehensive evaluation of 248 biomarker characteristics that is not attainable through analyses on a smaller number of 249 biomarkers acquired using unsubstantiated feature selection strategies. Since experiment 250 replicability has proven to be a great challenge in the development of clinically useful 251 biomarkers, it is vital to study the performance of biomarkers in a variety of settings, especially using different training and testing cohorts. Jackknifing and meta-dataset 253 permutation are, therefore, two key tools for prognostic biomarker research and can be 254 utilized to great effect in studies hindered by limited sample sizes and data access. score for each combination of patient P and subnetwork S is computed using the formula
where mRNA g,P is the mRNA abundance in patient P of gene g contained within subnetwork we thus calculate a risk score as measured by B using the formula
The median risk score is calculated for the training cohort and is then used as the break-point hundred between 500 and 800 inclusive). 250,000 biomarkers were jackknifed at each 302 subnetwork biomarker size for a total of 6,250,000 biomarkers and 500,000 biomarkers were 303 jackknifed at each gene biomarker size for a total of 22,000,000 biomarkers.
304
The jackknifing was performed to sample more gene biomarkers than subnetwork biomarkers 
Meta-dataset partitioning and concordance correlation calculations
318
As seen in and then sampled from that set.
327
The concordance correlation coefficient for multiple classes was used as first defined and subnetwork biomarkers had twenty matched observations of their performance as measured 331 by the raw hazard ratio returned by SIMMS or geneSIMMS.
332
Comparing subnetwork biomarker performance to peak gene biomarker performance 333 To determine peak gene biomarker performance on a given meta-dataset partition, we small training sets by the total number of biomarker genes.
